JPH06500323A - ウイルス性感染の治療方法 - Google Patents

ウイルス性感染の治療方法

Info

Publication number
JPH06500323A
JPH06500323A JP3514178A JP51417891A JPH06500323A JP H06500323 A JPH06500323 A JP H06500323A JP 3514178 A JP3514178 A JP 3514178A JP 51417891 A JP51417891 A JP 51417891A JP H06500323 A JPH06500323 A JP H06500323A
Authority
JP
Japan
Prior art keywords
tnf
ligand
residues
activity
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3514178A
Other languages
English (en)
Japanese (ja)
Inventor
ラスジェン，デボラ　アン
アストン，ロジャー
ランショー，イアン　アラステアー
Original Assignee
ペプチド　テクノロジィ　リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペプチド　テクノロジィ　リミテッド filed Critical ペプチド　テクノロジィ　リミテッド
Publication of JPH06500323A publication Critical patent/JPH06500323A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP3514178A 1990-08-27 1991-08-27 ウイルス性感染の治療方法 Pending JPH06500323A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPK197690 1990-08-27
AU1976 1990-08-27

Publications (1)

Publication Number Publication Date
JPH06500323A true JPH06500323A (ja) 1994-01-13

Family

ID=3774922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3514178A Pending JPH06500323A (ja) 1990-08-27 1991-08-27 ウイルス性感染の治療方法

Country Status (4)

Country Link
EP (1) EP0608212A1 (de)
JP (1) JPH06500323A (de)
CA (1) CA2090401A1 (de)
WO (1) WO1992003145A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587457A (en) * 1990-03-12 1996-12-24 Peptide Technology Limited Neutrophil stimulating peptides
US6375928B1 (en) * 1990-03-12 2002-04-23 Peptech Limited Neutrophil stimulating peptides
IT1254315B (it) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
ES2121907T3 (es) * 1992-08-28 1998-12-16 Bayer Ag Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
HRP20151440T1 (hr) 2008-12-29 2016-01-29 Trevena, Inc. Efektori beta-arestina i sastavi i metode u kojima se koriste
AU2013215269A1 (en) 2012-01-31 2014-08-21 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
US9518086B2 (en) 2014-02-07 2016-12-13 Trevena, Inc. Crystalline and amorphous forms of a β-arrestin effector
US9611293B2 (en) 2014-05-19 2017-04-04 Trevena, Inc. Synthesis of beta-arrestin effectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0415929A1 (de) * 1988-01-15 1991-03-13 Centocor, Inc. Hetero-unterbindende antikörper und ihre therapeutische benutzung
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards

Also Published As

Publication number Publication date
WO1992003145A1 (en) 1992-03-05
EP0608212A4 (de) 1993-10-20
EP0608212A1 (de) 1994-08-03
CA2090401A1 (en) 1992-02-28

Similar Documents

Publication Publication Date Title
JP4469013B2 (ja) 腫瘍壊死因子結合リガンド
Starnes Jr et al. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.
JP2638652B2 (ja) カケクチンと反応するモノクロナール抗体
US5902582A (en) Use of TFPI inhibitor for treatment of cancer
JP3541296B2 (ja) 腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法
CA2022429C (en) Methods and compositions for ameliorating the symptoms of sepsis
JPH06500323A (ja) ウイルス性感染の治療方法
KR20010102043A (ko) 항-혈관형성 요법 및 면역요법을 병용한 종양 및 전이의치료 방법
CN100457781C (zh) 抗癌抗体
JP2007277252A (ja) 腫瘍の治療及び予防のための自己抗体の使用方法
US20110182922A1 (en) Peptides of il1 beta and tnf alpha and method of treatment using same
JPH05505823A (ja) 細胞成長抑制法およびそれに有用な組成物
JP2002538170A5 (de)
Stein et al. Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual
Rathjen et al. Selective enhancement of the tumour necrotic activity of TNF α with monoclonal antibody
EP0525570A2 (de) TNF nachahmende anti-idiotypische Antikörper
JPS63290826A (ja) 特定の抗原に対する免疫応答を刺激する方法
Kim et al. Immobilized IgG immune complex induces secretion of tumor necrosis factor-a by porcine alveolar macrophages
WO1990011779A1 (en) Heteroconjugates
Alkan et al. Enhanced antiproliferative action of interferon targeted by bispecific monoclonal antibodies
AU654501B2 (en) Method of treating viral infection
Wang et al. Significance of alpha-fetoprotein in the development of novel therapeutic agents
EP0467416A1 (de) Antikörperzusammensetzungen von therapeutischen Mitteln mit verlängerter Serumhalbwertzeit
JPH02231431A (ja) 治療もしくは診断の目的でモノクローナル抗体をヒトに投与するための医薬製剤を得るためのヒトＩｇＧのＦｃフラグメント、Ｆｃフラグメント類似のペプチドまたはヒトＩｇＧの利用